New Enterprise Associates 17, L.P. 4
4 · Korro Bio, Inc. · Filed Mar 12, 2026
Research Summary
AI-generated summary of this filing
Korro Bio (KRRO) 10% Owner NEA 17 Buys $5M of Shares & Warrants
What Happened
New Enterprise Associates 17, L.P. (NEA 17), a reported 10% owner of Korro Bio, acquired common stock and pre‑funded warrants of Korro Bio on March 10, 2026. NEA 17 purchased 207,100 shares at $11.11 each for $2,300,881 and also acquired 242,945 pre‑funded warrants (derivative) at $11.11 each for $2,698,876, for a combined total of $4,999,757 (~$5.0M). The purchases were made from the issuer pursuant to a Subscription Agreement dated March 9, 2026 — a direct purchase (purchase code P), which is generally viewed as a bullish signal since the investor added to its position.
Key Details
- Transaction dates: March 10, 2026; Form 4 filed March 12, 2026 (report period 3/10/2026) — filing appears timely.
- Prices and amounts: 207,100 shares @ $11.11 = $2,300,881; 242,945 pre‑funded warrants @ $11.11 = $2,698,876. Total = $4,999,757.
- Shares owned after transaction: Not disclosed in the provided filing excerpt.
- Footnotes of note:
- Securities were acquired from the issuer under a Subscription Agreement dated March 9, 2026.
- The securities are directly held by NEA 17 and indirectly held by related NEA entities and managers, who disclaim beneficial ownership of portions where they have no pecuniary interest.
- The derivative instruments are pre‑funded warrants exercisable into common stock, but exercise is subject to a ownership cap (cannot be exercised to cause ownership to exceed 9.99% of outstanding shares unless the holder gives 61 days’ prior notice to raise that cap up to 19.99%).
Context
- This is an institutional (10% owner) purchase from the company, not an executive’s personal trade — institutional purchases can signal confidence but do not convey insider executive intent.
- The derivative portion are pre‑funded warrants (convertible to common stock). The filing notes an exercise limitation designed to avoid exceeding a specified ownership threshold.
- No indications of late filing were shown in the provided data.
Insider Transaction Report
Form 4Exit
Korro Bio, Inc.KRRO
New Enterprise Associates 17, L.P.
10% Owner
Transactions
- Purchase
Common Stock
[F1][F2]2026-03-10$11.11/sh+207,100$2,300,881→ 1,297,893 total - Purchase
Pre-Funded Warrants
[F1][F3][F2]2026-03-10$11.11/sh+242,945$2,698,876→ 242,945 totalExercise: $0.00→ Common Stock (242,945 underlying)
Footnotes (3)
- [F1]Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026.
- [F2]The securities are directly held by New Enterprise Associates 17, L.P. ("NEA 17") and are indirectly held by NEA Partners 17, L.P. ("NEA Partners 17"), the sole general partner of NEA 17, NEA 17 GP, LLC ("NEA 17 GP"), the sole general partner of NEA Partners 17, and the individual managers of NEA 17 GP (NEA Partners 17, NEA 17 GP and the individual managers of NEA 17 GP (collectively, the "Managers") together, the "Indirect Reporting Persons"). The Mangers are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony Florence, Jr., Mohamad Makhzoumi, Edward Mathers, Scott Sandell, Paul Walker and Rick Yang. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Indirect Reporting Persons have no pecuniary interest.
- [F3]The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%.
Signature
/s/ Zachary Bambach, attorney-in-fact|2026-03-12